Geneviève Gaucher, BPharm, PhD

Before joining Neurenati, Geneviève held positions of increasing responsibility as Director, Senior Director, and eventually Vice-President of Preclinical Development at Inversago Pharma, a Montreal-based company focusing on the development of next generation CB1 receptor blockers. In her role, Geneviève led a team of scientists and managed partnerships with academia and CROs, driving the successful completion of preclinical programs that supported Ph1 and Ph2 clinical trials with Monlunabant. Her efforts contributed to the company’s acquisition by Novo Nordisk in August 2023. Prior to Inversago, Geneviève was Manager of Research and Development at Confab Laboratories (Montreal) where she supervised a team and was involved in human and veterinary formulation development, spanning pre-formulation processes through full-scale production batches for validation and regulatory submission. Geneviève was also involved in the clinical development of GIC-1001 at gICare Pharma as Clinical Manager. She holds a bachelor’s degree in pharmacy from Université Laval and a Ph.D. in Pharmaceutical Sciences from the Faculty of Pharmacy of Université de Montréal.